Cardiac Dimensionscardiacdimensions has scored $8.5 million in equity financing, with the cash infusion coming from Arboretum Ventures of Michigan. The funding follows a $20 million round that closed in April, which included participation by M. H. Carnegie & Co. and Lumira Capital.

Founded in 2001, Kirkland-based Cardiac Dimensions has developed a way to address cardiovascular conditions with its Carillon Mitral Contour System, a non-surgical device that treats a form of congestive heart failure called mitral valve regurgitation, which affects how the heart properly pumps out blood. It’s the most common type of heart valve disorder, with about 70 percent of the 20 million people suffering from functional mitral regurgitation (FMR).

Proceeds from the financing will be used to support the completion of the company’s REDUCE FMR clinical trial, with the company’s technology designed to address of functional mitral regurgitation. In that condition, blood flow to the body is reduced due to an abnormally enlarged mitral valve.

Like what you're reading? Subscribe to GeekWire's free newsletters to catch every headline

Job Listings on GeekWork

Find more jobs on GeekWork. Employers, post a job here.